FMP

FMP

Enter

LFCR - Lifecore Biomed...

photo-url-https://images.financialmodelingprep.com/symbol/LFCR.png

Lifecore Biomedical, Inc.

LFCR

NASDAQ

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.

6.72 USD

0.355 (5.29%)

Historical Prices

From:

To:

6.126.26.36.46.56.66.76.7309:30 AM09:42 AM09:54 AM10:07 AM10:17 AM10:28 AM10:38 AM10:48 AM10:58 AM11:10 AM11:20 AM11:32 AM11:43 AM11:53 AM12:03 PM12:14 PM12:26 PM12:37 PM12:47 PM12:57 PM01:07 PM

About

ceo

Mr. Paul Josephs

sector

Healthcare

industry

Drug Manufacturers - Specialty & Generic

exchange

NASDAQ

Description

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and pro...

CIK

0001005286

ISIN

US5147661046

CUSIP

N/A

Address

3515 Lyman Boulevard

Phone

952 368 4300

Country

US

Employee

524

IPO Date

Feb 15, 1996

Financial Statement

-20M-10M010M20M30M40M2024 Q32024 Q42025 Q12025 Q22025 Q3RevenueNet Income

Earnings

-0.9-0.6-0.300.30.62023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q42025 Q1EPS Consensus

LFCR Financial Summary

CIK

0001005286

Exchange

NASDAQ

Industry

Drug Manufacturers -...

Sector

Healthcare

CUSIP

-

ISIN

US5147661046

Country

US

Price

6.71

Beta

0.8

Volume Avg.

211.81k

Market Cap

248.62M

Shares

-

52-Week

3.68-7.99

DCF

-6.52

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-4.63

P/B

-

Website

https://www.lifecore.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest LFCR News

Tony Dante

Apr 4, 2025

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Faces Financial Chal...

Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a company operating in the medical, biomedical, and genetics industry. It focuses on developing and manufacturing products for the healthcare sector. Despite its strategic initiatives, LFCR faces challenges in meeting financial expectations, as evidenced by its recent earnings report. On April 3, 2025, LFCR reported an earnings per share (EPS) of -$0.47, which was below the estimated EPS of -$0.14. This represents a significant negative earnings surpri...

Rayan Ahmad

Apr 1, 2025

Lifecore Biomedical, Inc. (NASDAQ: LFCR) Quarterly Earnings ...

Lifecore Biomedical, Inc. (NASDAQ: LFCR) is a contract development and manufacturing organization. It specializes in providing integrated services to the pharmaceutical and medical device industries. As LFCR prepares to release its quarterly earnings on April 3, 2025, Wall Street anticipates an earnings per share loss of $0.14 and revenue of around $33.2 million. LFCR's financial results for the third quarter of fiscal year 2025 will be shared after the market closes. Following the release, the...

Andrew Wynn

Jan 8, 2025

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Insider Purchase and...

Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a company involved in the development and manufacturing of biomaterials and medical devices. On January 8, 2025, Josephs Paul, the CEO and director, purchased 17,000 shares of LFCR at $5.74 per share. This acquisition increased his total holdings to 559,717 shares, indicating his confidence in the company's future. Despite this insider purchase, LFCR is currently under investigation by Bronstein, Gewirtz & Grossman, LLC. The firm is examining potential...

Tony Dante

Jan 2, 2025

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Financial Performanc...

Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a company that operates in the biomedical sector, focusing on the development and manufacturing of complex medical products. It competes with other firms in the industry by leveraging its expertise in biopolymer and pharmaceutical-grade manufacturing. LFCR's recent financial performance provides insights into its current market position and future potential. On January 2, 2025, LFCR reported an earnings per share (EPS) of -$0.2015, surpassing the estim...

Andrew Wynn

Dec 26, 2024

Lifecore Biomedical, Inc. (NASDAQ: LFCR) Quarterly Earnings ...

Lifecore Biomedical, Inc. (NASDAQ: LFCR) is preparing to release its quarterly earnings on January 2, 2025. As a fully integrated contract development and manufacturing organization, LFCR plays a significant role in the biomedical sector. Wall Street anticipates an earnings per share (EPS) loss of $0.27, with projected revenue of around $29.7 million. LFCR's financial metrics provide a deeper understanding of its market position. The company has a price-to-earnings (P/E) ratio of 35.87, indicat...

Zacks Investment Research

Mar 21, 2024

Lifecore (LFCR) Down 30% on Ending Strategic Review With No ...

Lifecore (LFCR) ends a year-long strategic review and will continue its operations on a stand-alone basis. The company also names a new CEO effective from May 20.

Zacks Investment Research

Feb 6, 2024

Strength Seen in Lifecore Biomedical (LFCR): Can Its 16.0% J...

Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Research

Sep 28, 2023

Will Lifecore Biomedical (LFCR) Report Negative Q1 Earnings?...

Lifecore Biomedical (LFCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep